Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.

@article{Gottschalk2003GeneratingCA,
  title={Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.},
  author={Stephen Gottschalk and Oliver L. Edwards and Uluhan Sili and M. Helen Huls and Tatiana Goltsova and Alan R. Davis and Helen E Heslop and Cliona M Rooney},
  journal={Blood},
  year={2003},
  volume={101 5},
  pages={1905-12}
}
The Epstein-Barr virus (EBV)-encoded LMP1 protein is expressed in EBV-positive Hodgkin disease and is a potential target for cytotoxic T-lymphocyte (CTL) therapy. However, the LMP1-specific CTL frequency is low, and so far the generation of LMP1-specific CTLs has required T-cell cloning. The toxicity of LMP1 has prevented the use of dendritic cells (DCs) for CTL stimulation, and we reasoned that an inactive, nontoxic LMP1 mutant (DeltaLMP1) could be expressed in DCs and would enable the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 54 references

Functional characterization of EBV peptide-specific T lymphocytes iso lated with MHC tetramers

G Koehne, I Leiner, +3 authors RJ. O’Reilly
Biol Blood Marrow Transplant • 2002

An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy

S Gottschalk, CYC Ng, CA Smith
Blood • 2001

Similar Papers

Loading similar papers…